1. Role: Associate Dean. Scope: College. Description: Lead research enterprise of the College of Pharmacy. Represent the College at the HSC level. Mentor researchers. Date: 2020.
Vibhudutta Awasthi, Ph.D.
Summary
My research interests are in the development of radiopharmaceuticals, small animal imaging and use of radiological imaging techniques to answer physiological questions. My current research focuses on the development of liposome encapsulated hemoglobin as an artificial oxygen carrier and he is studying cerebral oxygen metabolism using positron emission tomography. I am a board certified nuclear pharmacist with expertise in areas related to drug delivery, formulation development, nuclear pharmacy and small animal nuclear imaging.
Publications & Presentations
- 31. Houson H, Mdzinarishvili A, Awasthi V. PET imaging of ischemic brain stroke necrosis with novel agent F-18-Fluoroglucaric Acid. JOURNAL OF NUCLEAR MEDICINE. 2018; 59
32. Rao G, Nkepang G, Yari H, Xu J, Houson H, Teng C, Awasthi V. Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 with the 26S Proteasome. Frontiers in Chemistry . 2018; 6 : 392
33. Rao G, Houson H, Nkepang G, Yari H, Teng C, Awasthi V. Induction of Gut Proteasome Activity in Hemorrhagic Shock and its Recovery by Treatment with Diphenyldihaloketones CLEFMA and EF24. Am J Physiol Gastrointest Liver Physiol . 2018; 315 : G318-G327
34. Houson H, Nkepang G, Hedrick A, Awasthi V. Imaging of isoproterenol-induced myocardial injury with F-18-labeled fluoroglucaric acid in a rat model. Nucl Med Biol. 2018; 59 : 9-15
35. Awwad H O, Durand C D, Gonzalez L P, Tompkins P, Zhang Y, Lerner M R, Brackett D J, Sherry D M, Awasthi V, Standifer K. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behavioural brain research. 2018
Grants
- 1. Mechanism of F-18-fluorodeoxyglucarate accrual in myocardial injury. NHLBI. Start Date: 2024. End Date: 2029.
2. Developing PPARĪ³ acetylation inhibitor for the treatment of aging-related conditions. NIH. Start Date: 2021. End Date: 2026.
3. Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment. NIH. Start Date: 2021. End Date: 2026.
4. SBIR Phase I: Early-Stage Development of GPPD for Fatty Liver. NIH.
5. Surfactant protein-A regions as TLR4-immunomodulators. NIH. Start Date: 2017. End Date: 2023.
Awards and Honors
- 6. Sandra K and David L Gilliland Chair in Nuclear Pharmacy . Date: 2012.
7. Indo-American Society of Nuclear Medicine. President. Date: 2010.
Education
- 1. Degree: Ph D. Sanjay Gandhi Postgraduate Institute of Medical Sciences . Date: 1994.
2. Degree: M. Pharm.. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1990.
3. Degree: B. Pharm. Dr. Hari Singh Gour Vishwavidyalaya, Sagar (Formerly, University of Sagar). Date: 1988.
Administrative Assignments
2. Role: Director. Scope: University. Description: Direction and conduct of nuclear imaging services for biomedical investigators; Production of PET radiotracers for preclinical imaging and preparation for regulatory compliance for clinical applications; Consultations with researchers about imaging and tracer applications. Date: 2007.
External Connections and Partnerships
no results